Microvascular cerebral blood volume changes in aging APP swe/PS1dE9 AD mouse model: A voxel-wise approach

Brain Structure and Function

Volumn 218, Issue 5, 2013, Pages 1085-1098

  Zerbi, Valerio ^a,b   Jansen, Diane ^a   Dederen, Pieter J ^a   Veltien, Andor ^b   Hamans, Bob ^b   Liu, Yang ^c   Heerschap, Arend ^b   Kiliaan, Amanda J ^a  

^a RADBOUD UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; Amyloid ; APP PS1 mice; Cerebral blood volume; Voxel wise analysis

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; GLUCOSE TRANSPORTER 1; PRESENILIN 1;

AGING; ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; BRAIN BLOOD VESSEL; BRAIN BLOOD VOLUME; BRAIN CORTEX; BRAIN MICROVASCULATURE; CAPILLARY DENSITY; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MODEL; GENOTYPE; HIPPOCAMPUS; HISTOGRAM; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SENILE PLAQUE; SUBCORTEX; THALAMUS; TRANSGENIC MOUSE; VOXEL BASED MORPHOMETRY; WILD TYPE;

MUS; MUS MUSCULUS;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; BLOOD VOLUME DETERMINATION; CEREBRUM; GLUCOSE TRANSPORTER TYPE 1; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; MICROVESSELS; MODELS, ANIMAL; PRESENILIN-1; VASCULAR DISEASES;

EID: 84883151906     PISSN: 18632653     EISSN: 18632661     Source Type: Journal    
DOI: 10.1007/s00429-012-0448-8     Document Type: Article

References (58)

1. Altman R, Rutledge JC (2010) The vascular contribution to Alzheimer's disease. Clin Sci (Lond) 119:407-421
2. Ashburner J, Friston KJ (2000) Voxel-based morphometry - the methods. NeuroImage 11:805-821
3. Avants BB, Epstein CL, Grossman M, Gee JC (2008) Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal 12:26-41
4. Beckmann N, Schuler A, Mueggler T, Meyer EP, Wiederhold KH, Staufenbiel M, Krucker T (2003) Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer's disease. J Neurosci 23:8453-8459
5. Belliveau JW, Rosen BR, Kantor HL, Rzedzian RR, Kennedy DN, McKinstry RC, Vevea JM, Cohen MS, Pykett IL, Brady TJ (1990) Functional cerebral imaging by susceptibility-contrast NMR. Magn Reson Med 14:538-546
6. Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM (1995) MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 34:555-566
7. Breteler MM (2000) Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 21:153-160
8. Choeiri C, Staines W, Messier C (2002) Immunohistochemical localization and quantification of glucose transporters in the mouse brain. Neuroscience 111:19-34
9. de la Torre JC (2000a) Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease. Ann NY Acad Sci 924:136-152
10. de la Torre JC (2000b) Cerebral hypoperfusion, capillary degeneration, and development of Alzheimer disease. Alzheimer Dis Assoc Disord 14(Suppl 1):S72-S81
11. de la Torre JC (2000c) Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol Aging 21:331-342
12. de la Torre JC (2002) Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33:1152-1162
13. de la Torre JC (2004) Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3:184-190
14. de la Torre JC, Stefano GB (2000) Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide. Brain Res Brain Res Rev 34:119-136
15. Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM (1998) NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 40:793-799
16. Dorr A, Sled JG, Kabani N (2007) Three-dimensional cerebral vasculature of the CBA mouse brain: a magnetic resonance imaging and micro computed tomography study. NeuroImage 35:1409-1423
17. El Tayara Nel T, Delatour B, Volk A, Dhenain M (2010) Detection of vascular alterations by in vivo magnetic resonance angiography and histology in APP/PS1 mouse model of Alzheimer's disease. MAGMA 23:53-64
18. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. Academic Press, San Diego
19. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP (2006) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24:516-524
20. Ghiso J, Frangione B (2002) Amyloidosis and Alzheimer's disease. Adv Drug Deliv Rev 54:1539-1551
21. Grammas P (2000) A damaged microcirculation contributes to neuronal cell death in Alzheimer's disease. Neurobiol Aging 21:199-205
22. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 8:101-112
23. Hansen TD, Warner DS, Todd MM, Vust LJ (1989) Effects of nitrous oxide and volatile anaesthetics on cerebral blood flow. Br J Anaesth 63:290-295
24. Hao W, Liu Y, Liu S, Walter S, Grimm MO, Kiliaan AJ, Penke B, Hartmann T, Rube CE, Menger MD, Fassbender K (2011) Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology. Brain 134:278-292
25. Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, Stern Y (2009) Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 66:343-348
26. Hooijmans CR, Rutters F, Dederen PJ, Gambarota G, Veltien A, van Groen T, Broersen LM, Lütjohann D, Heerschap A, Tanila H, Kiliaan AJ (2007a) Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched typical Western diet (TWD). Neurobiol Dis 28:16-29
27. Hooijmans CR, Graven C, Dederen PJ, Tanila H, van Groen T, Kiliaan AJ (2007b) Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice. Brain Res 1181:93-103
28. Hooijmans CR, Van der Zee CE, Dederen PJ, Brouwer KM, Reijmer YD, van Groen T, Broersen LM, Lutjohann D, Heerschap A, Kiliaan AJ (2009) DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol Dis 33:482-498
29. Iadecola C (2004) Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 5:347-360
30. Iadecola C (2010) The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 120:287-296
31. Iadecola C, Zhang F, Niwa K, Eckman C, Turner SK, Fischer E, Younkin S, Borchelt DR, Hsiao KK, Carlson GA (1999) SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci 2:157-161
32. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17:157-165
33. Jankowsky JL, Slunt HH, Gonzales V, Jenkins NA, Copeland NG, Borchelt DR (2004) APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol Aging 25:885-892
34. Kalaria R (2002) Similarities between Alzheimer's disease and vascular dementia. J Neurol Sci 203-204:29-34
35. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron 37:925-937
36. Krucker T, Schuler A, Meyer EP, Staufenbiel M, Beckmann N (2004) Magnetic resonance angiography and vascular corrosion casting as tools in biomedical research: application to transgenic mice modeling Alzheimer's disease. Neurol Res 26:507-516
37. Larson ME, Lesne SE (2012) Soluble Aβ oligomer production and toxicity. J Neurochem 120(Suppl 1):125-139
38. Le Duc G, Peoc'h M, Remy C, Charpy O, Muller RN, Le Bas JF, Decorps M (1999) Use of T(2)-weighted susceptibility contrast MRI for mapping the blood volume in the glioma-bearing rat brain. Magn Reson Med 42:754-761
39. Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, Borchelt DR, Mamounas L, Lyons WE, Blue ME, Lee MK (2008) Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J Neurosci 28:13805-13814
40. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155:853-862
41. Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA (2008) Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci 28:6333-6341
42. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46:860-866
43. Meyer JS, Rauch GM, Rauch RA, Haque A, Crawford K (2000) Cardiovascular and other risk factors for Alzheimer's disease and vascular dementia. Ann NY Acad Sci 903:411-423
44. Meyer EP, Ulmann-Schuler A, Staufenbiel M, Krucker T (2008) Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc Natl Acad Sci USA 105:3587-3592
45. Niwa K, Carlson GA, Iadecola C (2000) Exogenous Aβ1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab 20:1659-1668
46. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C (2002a) Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol 283:H315-H323
47. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C (2002b) Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 9:61-68
48. Peppiatt CM, Howarth C, Mobbs P, Attwell D (2006) Bidirectional control of CNS capillary diameter by pericytes. Nature 443:700-704
49. Sawiak SJ, Wood NI, Williams GB, Morton AJ, Carpenter TA (2009) Voxel-based morphometry in the R6/2 transgenic mouse reveals differences between genotypes not seen with manual 2D morphometry. Neurobiol Dis 33:20-27
50. Skoog I, Gustafson D (2002) Hypertension and related factors in the etiology of Alzheimer's disease. Ann NY Acad Sci 977:29-36
51. Tropres I, Grimault S, Vaeth A, Grillon E, Julien C, Payen JF, Lamalle L, Decorps M (2001) Vessel size imaging. Magn Reson Med 45:397-408
52. Walsh DM, Selkoe DJ (2007) Aβ oligomers - a decade of discovery. J Neurochem 101:1172-1184
53. Weidensteiner C, Metzger F, Bruns A, Bohrmann B, Kuennecke B, von Kienlin M (2009) Cortical hypoperfusion in the B6.PS2APP mouse model for Alzheimer's disease: comprehensive phenotyping of vascular and tissular parameters by MRI. Magn Reson Med 62:35-45
54. Weiss HR, Buchweitz E, Murtha TJ, Auletta M (1982) Quantitative regional determination of morphometric indices of the total and perfused capillary network in the rat brain. Circ Res 51:494-503
55. Wu EX, Wong KK, Andrassy M, Tang H (2003) High-resolution in vivo CBV mapping with MRI in wild-type mice. Magnetic Reson Med 49:765-770
56. Wu EX, Tang H, Asai T, Yan SD (2004) Regional cerebral blood volume reduction in transgenic mutant APP (V717F, K670N/M671L) mice. Neurosci Lett 365:223-227
57. Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178-201
58. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12:723-738